Salem Erode Investments board meets 2026: 3 key items

What Salem Erode Investments told BSE

Salem Erode Investments Ltd (BSE scrip: 540181) has made a series of board meeting intimations to BSE India, setting out distinct agendas across late FY26. The disclosures cover fund raising via non-convertible debentures (NCDs), approval of quarterly financial results, and a proposal linked to a previously approved right issue.

The company’s notices were filed under Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Each intimation indicates the meeting will be held at the company’s corporate office, as stated in the filings.

March 24, 2026 meeting: proposal tied to right issue

In the latest sequence of intimations mentioned in the provided text, Salem Erode Investments informed BSE that its Board of Directors is scheduled to meet on 24/03/2026. The stated agenda includes considering and approving a proposal to supersede the right issue approval.

The disclosure does not provide further details in the text shared, such as the size of any proposed issuance, revised terms, or timelines. It also does not state whether the company intends to replace the right issue with an alternate fund-raising instrument. The only confirmed element is that the board is expected to consider and approve a proposal related to superseding the earlier right issue approval.

February 12, 2026 meeting: Q3FY26 results on the agenda

Salem Erode Investments also notified BSE that a board meeting is scheduled on 12/02/2026. The purpose, as stated, is to consider and approve the company’s unaudited standalone financial results for the quarter ended December 31, 2025.

The same update is described as a review and approval of the unaudited standalone financial results for the third quarter of fiscal year 2026. The intimation was communicated to BSE on February 07, 2026, under Regulation 29, according to the provided text.

The notice also includes investor contact details for queries relating to the board meeting and the financial results. As provided, the company can be reached at +91 0480 2828071 and via email at salemerodeinvestmentsltd@gmail.com and cs@salemerode.com.

January 30, 2026 meeting: NCD fund raising proposal

Another board meeting, scheduled for Friday, January 30, 2026, is intended to consider fund raising by issuing Secured Redeemable Non-Convertible Debentures on a private placement basis. The intimation notes that the meeting will be held at the company’s corporate office.

The text states that the company notified BSE under Regulation 29 compliance requirements. It also states that Company Secretary Visakh T V signed the official communication dated January 27, 2026.

The material shared does not specify the fund raise amount, coupon, tenure, security details, or the targeted investor category for the private placement. Only the instrument type and placement method are explicitly mentioned.

A related December 23, 2025 board meeting intimation

Separately, the provided text also references an earlier intimation stating that the board meeting was scheduled on 23/12/2025, inter alia, to consider and approve fund raising through Secured Redeemable Non-Convertible Debentures on a private placement basis.

No additional information is provided in the text about the outcome of that meeting, whether any NCDs were issued, or if the agenda was deferred. The disclosure in the shared content is limited to the scheduling and agenda.

What these disclosures signal for governance and compliance

Board meeting intimations are a routine but important part of market disclosure, particularly when the agenda involves fund raising or financial results. Under SEBI’s listing framework, prior intimation helps ensure that price-sensitive discussions are not conducted without public notice.

In Salem Erode Investments’ case, the notices cover three distinct decision points: reviewing quarterly results, evaluating a debt raise through secured redeemable NCDs, and considering a proposal that would supersede a right issue approval. Taken together, these items indicate that the board is expected to take decisions spanning both financial reporting and capital-raising structure.

Market impact: what investors can and cannot conclude

From the information provided, investors can only conclude that the company has scheduled meetings with the above agendas, and that the company has communicated them to BSE as required. The text does not provide financial performance figures for Q3FY26, nor does it provide the size or pricing of any proposed fund raising.

Similarly, the right issue-related agenda confirms board consideration on March 24, 2026, but does not establish what the replacement or superseding proposal will be. Any inference about dilution, debt levels, or changes in capital structure would require details not present in the shared text.

Key facts table

What to watch next

The next concrete updates will likely come through outcomes filed after each board meeting, especially for items tied to fund raising and the right issue supersession proposal. For the February 12, 2026 meeting, the key awaited disclosure is the unaudited standalone financial results for the quarter ended December 31, 2025.

For the January 30, 2026 NCD agenda and the March 24, 2026 right issue-related agenda, investors will look for any post-meeting filings that clarify approvals, timelines, and terms, if any decisions are taken.